Abstract
Characterize the pathophysiology of pediatric asthma made rapid progress over the last decade. Its therapeutic strategy also changed to anti-inflammatory therapy for chronic bronchial inflammation. Points that need to be clarify in the next decade are when anti-inflammatory therapy starts in infant asthma, building consensus of asthma control to reach therapeutic destination and developing method to step down anti-inflammatory therapy.
GINA and EPR-3 have changed gradually and describe these points. We are not merely for making copy of guideline abroad but also developing original guideline in consideration of social background.
